Research programme: natural killer cell tumour targeting immune cell agonists - Bicycle Therapeutics
Alternative Names: Immune and tumour cell targeting bicycles - Bicycle Therapeutics; Natural killer cells and tumour targeting bicycles - Bicycle Therapeutics; NK TICA; NK-TICAsLatest Information Update: 25 May 2023
At a glance
- Originator Bicycle Therapeutics
- Class Antineoplastics; Bicyclic peptides; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 17 Apr 2023 Pharmacodynamic and adverse event data from preclinical studies in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research, 2023 (AACR-2023)
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research
- 11 Mar 2021 Natural killer cell tumour targeting immune cell agonists is available for licensing as of 11 Mar 2021. https://www.bicycletherapeutics.com/ 803549144